SAN
DIEGO, Oct. 20, 2022 /PRNewswire/ -- Inhibrx,
Inc. (Nasdaq: INBX), a clinical-stage biopharmaceutical company
dedicated to the development of therapeutics for oncology and rare
diseases, today announced it will be presenting at multiple
upcoming scientific conferences.
American Conference on Pharmacometrics (ACoP)13th
Annual Meeting
October 30th
– November 2nd, 2022 – Aurora, Colorado
Title: PK/PD Characterization of INBRX-101, a
Novel, Recombinant Alpha-1 Antitrypsin Fusion Protein, in Patients
with Alpha-1 Antitrypsin Deficiency
Lead Author: Sharvari Bhagwat
Poster ID: T-009; Abstract ID: PMX436
Poster Presentation on Tuesday, November
1st, 2022 between 8:30
a.m. – 5:30 p.m. Eastern
Time
Society for Immunotherapy of Cancer (SITC) 37th
Annual Meeting
November
8th – 12th, 2022 – Boston, Massachusetts
Title: Development of a Molecular Targeted
Cytokine that Specifically Expands Vg9Vd2 T-cells and Potentiates
Anti-tumor Activity
Lead Author: Bryan Becklund, PhD
Abstract: 1077
Poster Presentation on Thursday, November
10th, 2022 from 9:00
a.m. – 9:00 p.m. Eastern Time
and Friday, November 11th,
2022 from 9:00 a.m. – 8:30 p.m. Eastern Time
Connective Tissue Oncology Society (CTOS) 2022 Annual
Meeting
November
16th – 19th, 2022 - Vancouver, BC, Canada
Title: Updated Efficacy and Safety of the
Tetravalent Death Receptor 5 Agonist INBRX-109 in Patients with
Chondrosarcoma: Data from the Phase 1 Expansion Cohorts
Lead Author: Sant P. Chawla, MD
Abstract: 2206531, Poster (P 043)
Vivek Subbiah, MD to Present Virtual
Poster Presentation on Saturday, November
19th, 2022 from 4:36
p.m. – 4:44 p.m. Eastern
Time
Title: INBRX-109 in Ewing Sarcoma: Preclinical
Rationale for Initiation of a Phase 1 Chemotherapy Combination
Expansion Cohort
Lead Author: Nehal J. Lakhani, MD,
PhD
Abstract: 2206541, Poster (P 324)
Poster Walk and Reception on Thursday,
November 17th, 2022 at 5:00 p.m. – 7:00 p.m.
Eastern Time
Title: A Randomized, Placebo-Controlled Phase 2
Trial of INBRX-109 in Unresectable or Metastatic Conventional
Chondrosarcoma
Lead Author: Robin Lewis L. Jones,
MD
Abstract: 2206600, Poster (P 322)
Poster Walk and Reception on Thursday,
November 17th, 2022 at 5:00 p.m. – 7:00 p.m.
Eastern Time
The scientific posters will be accessible through a link on the
investors' section of Inhibrx's website at
https://inhibrx.investorroom.com/events-and-presentations upon
commencement of each respective presentation.
About Inhibrx, Inc.
Inhibrx is a clinical-stage biopharmaceutical company focused on
developing a broad pipeline of novel biologic therapeutic
candidates in oncology and orphan diseases. Inhibrx utilizes
diverse methods of protein engineering to address the specific
requirements of complex target and disease biology, including its
proprietary sdAb platform. Inhibrx has collaborations with 2seventy
bio (formerly bluebird bio), Bristol-Myers Squibb and Chiesi. For
more information, please visit www.inhibrx.com.
Investor and Media Contact:
Kelly Deck
CFO
kelly@inhibrx.com
858-795-4260
View original content to download
multimedia:https://www.prnewswire.com/news-releases/inhibrx-announces-participation-in-upcoming-scientific-conferences-301655425.html
SOURCE Inhibrx Inc.